Probiotics, prebiotics and symbiotic in inflammatory bowel diseases state-of-the-art and new insights.

Cottone,M; Bellavia,M; Rossi,F; Facella,T; Damiani,P; Zeenny,Mn; Damiani,F; Abbruzzo,A; Cocchi,M; Jurjus,A; Spinelli,G; Raimondo, D

Risultato della ricerca: Article

19 Citazioni (Scopus)

Abstract

Inflammatory bowel disease (IBD) consists of two distinct clinical forms, ulcerative colitis (UC) and Crohn s disease (CD), with unknown aetiology, which nevertheless are considered to share almost identical pathophysiological backgrounds. Up to date, a full coherent mechanistic explanation for IBD is still lacking, but people start to realize that the pathogenesis of IBD involves four fundamental components: the environment, gut microbiota, the immune system and the genome. As a consequence, IBD development might be due to an altered immune response and a disrupted mechanism of host tolerance to the non-pathogenic resident microbiota, leading to an elevated inflammatory response. Considering the available data arising from the scientific literature, here reviewed, in CD, a benefit of probiotics remains unproven; in UC, a benefit of probiotics remains unproven, even if E. coli Nissle 1917seems promising in maintaining remission and it could be considered an alternative in patients intolerant or resistant to 5-ASA preparations; in pouchitis, small controlled trials suggest a benefit from VSL no. 3 in the primary and secondary prevention of pouchitis; in IBD-associated conditions, a benefit of probiotics remains unproven. However, well-designed randomized control clinical trials are necessary to understand the undoubted role of these agents in the management of gut physiology in health and disease
Lingua originaleEnglish
pagine (da-a)919-933
Numero di pagine15
RivistaJOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS
Stato di pubblicazionePublished - 2013

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Cancer Research
  • Physiology (medical)
  • Endocrinology
  • Oncology
  • Immunology
  • Physiology
  • Immunology and Allergy

Cita questo

Cottone,M; Bellavia,M; Rossi,F; Facella,T; Damiani,P; Zeenny,Mn; Damiani,F; Abbruzzo,A; Cocchi,M; Jurjus,A; Spinelli,G; Raimondo, D (2013). Probiotics, prebiotics and symbiotic in inflammatory bowel diseases state-of-the-art and new insights. JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS, 919-933.